Search

everythinglearnresearchcommunity

for

Search:↓

Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.

A recent discovery in hair cloning identified a previously unknown cell type essential for hair follicle growth, which could potentially make lab-grown hair viable if translated to humans. However, skepticism remains due to past delays and the challenges of replicating results in humans and making the process affordable.

Oral minoxidil and finasteride can lead to quick hair growth, with some users noticing changes in as little as 2-3 weeks, though head hair may take longer. Many prefer oral minoxidil over topical due to convenience, and some also use ketoconazole shampoo and other topical treatments.

Finasteride prices vary widely across Europe, with some users opting to buy 5mg tablets and split them to save money. Many find 1mg tablets more expensive, and some suggest importing from countries like India for cheaper options.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

A user increased their dutasteride dose to 2.5 mg and oral minoxidil to 5 mg after losing hair regrowth, and also started using 2% ketoconazole and microneedling. Another user suggested these changes are meaningful and recommended splitting doses throughout the day for better absorption.

The conversation is about hair loss treatments, specifically the use of 1 mg finasteride and 1.5 mg oral minoxidil over two years, with consideration of a future hair transplant and possibly switching to dutasteride. Users discuss their own experiences and suggest trying different treatments like minoxidil 5%.

Hair loss can cause psychological distress, but maintaining optimism and self-improvement is crucial. Treatments like minoxidil, finasteride, and potential new options like clascoterone offer hope, though side effects can occur.

A trans woman is using 10 mg oral minoxidil, dutasteride, and estradiol for hair regrowth and is also doing dermastamping despite the pain. Users discuss the benefits of dermastamping for serum absorption and hair follicle stimulation, with some expressing surprise at the high minoxidil dosage.

The conversation jokes about hair loss treatments, mentioning finasteride, minoxidil, dutasteride, microneedling, ketoconazole shampoo, and rosemary oil as if they were players in a game. Some users also discuss the use of finasteride for prostate issues and the possibility of splitting the dose.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

Taking 5mg oral minoxidil at night instead of splitting 2.5mg doses, with the rationale that a single larger dose may provide a stronger activation for hair follicles and reduce peak-related side effects. Some users report sleep issues with nighttime dosing, while others find it beneficial; opinions on effectiveness and side effects vary.

Oral minoxidil dosing should be based on body weight to minimize side effects, with higher doses increasing risks like pericardial effusion. Combining oral minoxidil with topical treatments and finasteride can improve hair growth, but regular heart health monitoring is essential.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

Oral minoxidil is more effective than topical minoxidil for hair regrowth but may cause side effects like heart issues and increased body hair. Combining it with finasteride is common for better results, though side effects vary.

A 23-year-old is using 2.5 mg dutasteride, 5 mg oral minoxidil, RU58841, a laser cap, and PRF injections for hair loss. They are hesitant about microneedling due to concerns about RU58841 absorption and are considering other treatments.

Switching from topical to oral minoxidil, specifically using split dosing, led to significant hair regrowth and reduced side effects for the user. The combination of oral minoxidil and finasteride proved more effective than previous topical treatments.

Oral minoxidil is effective for hair loss but may cause side effects like increased heart rate and edema. Finasteride is recommended, with dutasteride as an alternative if needed.

Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.

Stemson Therapeutics has shut down, disappointing those seeking a hair loss cure. Current treatments like minoxidil, finasteride, and dutasteride are discussed, with some users experiencing side effects and exploring alternatives like PP405.

Oral minoxidil is causing significant blood pressure fluctuations and increased heart rate, leading the user to consider switching to topical minoxidil and tretinoin. The user plans to consult a cardiologist and is likely to stop using oral minoxidil.

Oleic acid and ethanol are being considered for hair regrowth, with some users planning to self-experiment. There is skepticism about their effectiveness, and ongoing use of treatments like finasteride and minoxidil is mentioned.